Colesevelam possesses antidiabetic properties, which could potentiate sulphonylurea or insulin-induced hypoglycemia; clinically significant hypoglycemia, as a side effect to bile acid sequestrants, may be under-recognized in clinical practice. Here, INS is linked to Hypoglycemia.